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This study aimed to evaluate the activity of essential oils (EOs) against Streptococcus mutans biofilm by chemically characterizing
their fractions responsible for biological and antiproliferative activity. Twenty EOwere obtained by hydrodistillation and submitted
to the antimicrobial assay (minimum inhibitory (MIC) and bactericidal (MBC) concentrations) against S. mutans UA159. Thin-
layer chromatography and gas chromatography/mass spectrometry were used for phytochemical analyses. EOs were selected
according to predetermined criteria and fractionated using dry column; the resulting fractions were assessed by MIC and MBC,
selected as active fractions, and evaluated against S. mutans biofilm. Biofilms formed were examined using scanning electron
microscopy. Selected EOs and their selected active fractions were evaluated for their antiproliferative activity against keratinocytes
and seven human tumor cell lines. MIC and MBC values obtained for EO and their active fractions showed strong antimicrobial
activity. Chemical analyses mainly showed the presence of terpenes. The selected active fractions inhibited S. mutans biofilm
formation (P < 0.05) did not aﬀect glycolytic pH drop and were inactive against keratinocytes, normal cell line. In conclusion, EO
showed activity at low concentrations, and their selected active fractions were also eﬀective against biofilm formed by S. mutans
and human tumor cell lines.
1. Introduction
Despite the implementation of measures to control and
treat dental caries with fluoride, they remain the most
prevalent dental disease in many countries [1]. Caries are a
multifactorial infectious disease caused by accumulation of
biofilm on tooth surface [2]. Manifestations of the disease
occur when there is an imbalance between the biofilm and
the host due to changes in biofilm matrix pH caused by
diet, microorganisms, or salivary flow and their components
[3, 4].
Streptococcus mutans is considered the most cariogenic
of all oral streptococci [5]. S. mutans is able to colonize the
tooth surface and to produce large amounts of extra and
intra-cellular polysaccharides. This microorganism is also
highly acidogenic and aciduric, and it metabolizes several
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salivary glycoproteins, thus being responsible for the initial
stage of oral biofilm formation and caries lesions [6].
Several products have been used to control dental caries,
such as fluoride, chlorhexidine, and their associations [7].
However, natural products have contributed significantly
to the discovery of chemical structures to create new
medicaments to be used as innovative therapeutic agents
against this prevalent disease [8, 9].
Essential oils (EOs) are important for their detected
antimicrobial activity [10–12] including that against S.
mutans [13]. They are complex, volatile, natural compounds
formed by aromatic plants as secondary metabolites [14].
They are known for their bactericidal, virucidal, fungici-
dal, sedative, anti-inflammatory, analgesic, spasmolytic, and
locally anesthetic properties [14]. The presence of complex
chemical structures constituted of several groups, such as
terpenes and terpenoids, aromatic and aliphatic constituents,
all characterized by low molecular weight, may explain their
successful bacteriostatic and bactericidal action [14].
Additionally, it was attested that the antimicrobial activ-
ity of a natural product, such as EO, is important to evaluate
its eﬀects on human normal cell lines and also against human
tumor cell lines in order to evidence potential toxicity on
human healthy and tumor cell lines [15]. For this reason, it is
important that extensive studies involving EO as well as other
sources of natural medicines are carried out.
The aim of this study was to evaluate the activity of EO
and fractions against planktonic cells of S. mutans and
also the selected active fractions of EO were chemically
characterized and evaluated against mutans biofilm and
antiproliferative activity on human cells.
2. Materials andMethods
2.1. Medicinal Plants. We studied 20 medicinal and aromatic
plants (Table 1), which were obtained from the germoplasm
bank of the Collection of Medicinal and Aromatic Plants
(CPMA) of the Research Center for Chemistry, Biology
and Agriculture (CPQBA), University of Campinas (UNI-
CAMP), Sa˜o Paulo, Brazil (http://www.cpqba.unicamp.br/),
and identified by Glyn M. Figueira, curator of CPMA.
The plants were collected from November 2009 to
January 2011, during the morning, after the dew point has
been reached. The vouchers of each species were deposited
in the herbarium of the Institute of Biology, at UNICAMP-
UEC, and also registered in the herbarium of CPQBA,
receiving identification numbers (CPMA number).
2.2. Essential Oil Extraction. EOs were obtained from 100 g
of aerial fresh plant parts by hydrodistillation using a
Clevenger-type system, for 3 hours. The aqueous phase
was extracted with 50mL of dichloromethane. Then, the
organic layer was separated, dried over anhydrous sodium
sulphate (Na2SO4), and filtered; the solvent was removed by
vacuum evaporation at room temperature, resulting in EO.
Oil samples were stored at −25◦C in sealed glass vials [11].
2.3. Fractionation of Essential Oils. In order to select the EO
that should be fractionated, we predetermined some criteria:
best antimicrobial activity (MIC < 250 µg/mL), extract yield
(>0.5%, except for Coriandrum sativum EO), commercial
availability, presence of the EO in aerial parts of plants, and
easy cultivation. The resulting fractions were also submitted
to the antimicrobial assay.
Fractionation was performed using dry column chro-
matography (cellulose 2 cm × 20 cm) with Si gel 60
(Merck, Darmstadt, Germany) as the stationary phase and
dichloromethane as the mobile phase, previously chosen
by thin-layer chromatography (TLC), visualized under UV
254 nm, followed by anisaldehyde solution application and
drying at 105◦C for 5min. After elution, columns were
cut into diﬀerent parts for each EO, according to polarity
and extraction, using dichloromethane. The fractions so
obtained were analyzed using TLC and gas chromatography
coupled to mass spectrometry (GC-MS) and then bioguided
using the antimicrobial assays [16]. All chemical wastes
generated during this study were treated according to the
Environmental Ethics Committee of UNICAMP (324/2009).
2.4. Analyses of the Selected Active Fractions using GC-
MS. The chemical composition of each selected active
fraction was evaluated using a Hewlett-Packard 6890 gas
chromatograph equipped with an HP-5975 mass selective
detector and HP-5 capillary column (30m × 0.25mm ×
0.25 µm). GC-MS was performed using split injection with
the injector set at 220◦C, the column set at 60◦C with a
heating ramp of 3◦C/min and a final temperature of 240◦C,
and the MS detector set at 250◦C. Helium was used as a
carrier gas at 1mL/min. The GC-MS electron ionization
system was set at 70 eV. The quantitative analyses were
performed using a Hewlett-Packard 5890 gas chromatograph
equipped with a flame ionization detector under the same
conditions previously described. A sample of each EO or
its selected active fraction was solubilized in ethyl acetate
(15mg/mL) for the analysis. Retention indices (RIs) were
determined using injection of hydrocarbon standards and
EO samples under the same conditions described above. The
oil components were identified by comparison with data
described in the literature and the profiles in the NIST 05
mass spectral library [11, 17].
2.5. Microorganisms. For the development of this study,
Streptococcus mutans UA159 was used.
2.6. Antimicrobial Assay. We tested 20 EOs using the antimi-
crobial assay and selected them according to pre-determined
criteria (item 2.3) before being fractionated and continuing
the bioguided study.
MIC test was carried out using tissue culture microplates
(96 wells) containing 100 µL/well BHI (Brain Heart Infusion,
Difco, Franklin Lakes, NJ, USA) medium [18]. The stock
solutions of EO and fractions from selected EO (item 2.3)
were diluted with propylene glycol (4mg/mL), transferred
to the first well, and serial dilutions were performed to
obtain concentrations ranging from 7.81 to 1000 µg/mL. We
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used 0.12% chlorhexidine (Sigma-Aldrich, St. Louis, MO,
USA) as positive control and propylene glycol 6.25% as
negative control. The bacterial inoculum (1 × 106 UFC/mL)
was added to all wells, and the plates were incubated at
37◦C and 5% CO2 for 24 hours. MIC was defined as the
lowest concentration of EO or fraction from selected EO
that inhibited microorganism visible growth indicated by
resazurin 0.01% (Sigma-Aldrich, St. Louis, MO, USA) [19].
To determine MBC, an aliquot of each incubated well
with concentrations higher than MIC was subcultured on
BHI medium supplemented with 5% defibrinated sheep
blood using a Whitley Automatic Spiral Plater (Don Whitley
Scientific Limited, Shipley, West Yorkshire, UK). MBC was
defined as the lowest concentration of EO or fraction that
allowed no visible growth on the test medium.
To determine the nature of antibacterial eﬀect of EO and
fractions, the MBC :MIC ratio for bacteria was used [20].
When MBC :MIC ratio for S. mutans was between 1 : 1 and
2 : 1, the EO or fraction from selected EO was considered
bactericidal against this microorganism [20], and when the
ratio was higher than 2 : 1, it was considered bacteriostatic.
2.7. Action of Selected Active Fractions from Selected EO against
S. mutans Biofilm. We tested 20 EOs, and those that fulfilled
the pre-determined criteria (item 2.3) were selected to be
chemically fractionated. The resulting fractions were also
tested using the antimicrobial assay and selected according
to MIC and MBC results and yields. The selected active
fractions were then assessed regarding their action against S.
mutans biofilm.
2.7.1. Inhibition of S. mutans Biofilm Growth. In order to
evaluate the antimicrobial activity of EO selected active
fractions against the formation of S. mutans biofilm, the
samples were placed, at diﬀerent concentrations (7.81–
1000 µg/mL), in the wells of sterile polystyrene U-bottom
microtiter plates, previously treated with saliva (the use of
human saliva in this study was approved by the Research
Ethics Committee of the Piracicaba Dental School, State
University of Campinas (UNICAMP) (Approval 087/2011))
[21]. S. mutans cells (1.0 × 107 cells/mL in BHI medium)
were added to wells containing BHI medium with 2%
sucrose and the samples were incubated at 37◦C for 18 hours.
Biofilm growth was revealed and quantified using the crystal
violet staining method and measuring absorbance at 575 nm
[11, 22].
After 18 hours of incubation, the spent medium was
aspirated, nonadhered cells were removed, the wells were
washed three times with sterile distilled water, and the
plates were dried for 45min before carrying out biofilm
quantification [22].
2.7.2. Glycolytic pH-Drop Assay. The eﬀect of EO selected
active fractions against S. mutans biofilm was measured
using the standard glycolytic pH-drop assay [23]. Biofilm
growth was carried out as previously described (item 2.7.1),
in sterile polystyrene U-bottom microtiter plates without
fractions. The biofilms so obtained were washed twice with
0.9% NaCl solution and salt solution (50mM KCl + 1.0mM
MgCl2), containing EO selected active fractions at diﬀerent
concentrations (1000, 500, and 250 µg/mL), and vehicle
(25% propylene glycol, v/v) was added. The pH was adjusted
to 7.2 with 0.1M KOH solution, and glucose was added to a
final concentration of 1%, and pH-drop was assessed using
Orion pH glass electrode attached to Orion 290 A+ pHmeter
(Orion Scientific, Houston, TX, USA) for 90min.
2.8. Scanning Electron Microscopy (SEM). In order to evalu-
ate S. mutans integrity using SEM, biofilms were first devel-
oped in Lab-Tek chambered coverglass (Nunc, Naperville, IL,
USA), as described previously (item 2.7.1), were treated with
vehicle (6.12% propylene glycol) or had their active fractions
selected at concentrations able to inhibit more than 90%
of S. mutans biofilm formation. Samples were fixed in 4%
glutaraldehyde (v/v) in phosphate-buﬀered saline (PBS) at
room temperature for 12–24 hours. After this procedure, the
biofilms were dehydrated through a graded series of ethanol
(50% to 100%), dried to a critical point, coated with gold,
and observed using a scanning electron microscope JEOL
JSM5600LV (JEOL Ltd., Tokyo, Japan) [11, 24].
2.9. Antiproliferative Assay. The in vitro antiproliferative
assay [25] was performed in the present study using a human
keratinocyte (HaCat) cell line, kindly donated by Dr. Ricardo
Della Coletta (FOP, UNICAMP, Brazil), and seven human
tumor cell lines (U251 (glioma), MCF-7 (breast), NCI-
ADR/RES (ovarian expressing phenotype multiple drugs
resistance), 786-0 (renal), NCI-H460 (lung, nonsmall cells),
PC-3 (prostate), and OVCAR-03 (ovarian), kindly provided
by M. A. Frederick (National Cancer Institute, USA). Stock
and experimental cultures were grown inmedium containing
5mL RPMI-1640 (Gibco-BRL, Grand Island, NY, USA)
supplemented with 5% fetal bovine serum (Gibco-BRL,
Grand Island, NY, USA). A penicilline-streptomicine mix-
ture (1000U/mL : 1000mg/mL, 1mL/L RPMI) was added
to experimental cultures. Cells in 96-well plates (100 µL
cells/well) were exposed to each EO and selected active
fractions in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St.
Louis, MO, USA) (0.25, 2.5, 25, and 250 µg/mL) at 37◦C and
5% CO2 for 48 hours. Final DMSO concentration did not
aﬀect cell viability. Before (T0 plate) and after sample addi-
tion (T1 plates), cells were fixed with 50% trichloroacetic acid
and cell proliferation was determined by spectrophotometric
quantification (540 nm) of cellular protein content using
sulforhodamine B assay. Using the concentration-response
curve for each cell line, the total growth inhibition (TGI)
was determined by nonlinear regression analysis using the
software Origin 8.0 (OriginLab Corporation, Northampton,
MA, USA) [26, 27].
2.10. Statistical Analysis. An exploratory data analysis was
performed to determine the most appropriate statistical
test. Inhibition of biofilm growth, and glycolytic pH-drop
data were compared using the nonparametric Kruskal-Wallis
test. P value < 0.05 was considered statistically significant.
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Triplicates from at least three separated experiments were
conducted in each assay.
3. Results
3.1. Essential Oils and Fraction Yields. The EO yields,
expressed in relation to dry weight of plant material (%,
w/w), are shown in Table 1.
According to pre-determined criteria (item 2.3), four
EOs were selected to be fractionated using dry column as
follows: A. gratissima, B. dracunculifolia, C. sativum, and L.
sidoides.
The yields of the fractions from selected EO were
expressed as a function of the respective EO yield (%, w/w)
and are shown in Table 2. The yields ofA. gratissima fractions
ranged from 14.4% to 29%, B. dracunculifolia from 20.1% to
30.6%, C. sativum from 4.9% to 30.9%, and L. sidoides from
1.7% to 33.3%.
3.2. Antimicrobial Activity. MIC and MBC values for all
tested EO are shown in Table 1. MIC values ranged from
31.2 to 500 µg/mL, and MBC values ranged from 62.5 to
1000 µg/mL. The highest activities were observed for A.
gratissima and A. triphylla (125–250 µg/mL), B. dracunculi-
folia, L. sidoides, M. glomerata, S. guianenses, S. aromaticum
(62.5–125 µg/mL), and C. sativum (31.2–62.5 µg/mL).
Based on pre-determined criteria (item 2.3), four EOs
(A. gratissima, B. dracunculifolia, C. sativum, and L. sidoides)
were selected to be fractionated. MIC and MBC values of
fractions from selected EO are shown in Table 2. MIC values
obtained for all fractions ranged from 15.6 to 500 µg/mL,
and MBC values ranged from 31.2 to 1000 µg/mL. The
highest activities were observed for the fractions Ag4 (31.2–
62.5 µg/mL), Bd2 (15.6–31.2 µg/mL), Cs4(15.6–31.2 µg/mL),
and Ls3 (62.5–125 µg/mL).
TheMBC :MIC ratio (Table 1) showed that most EOs are
bactericidal, except for B. dracunculifolia, E. florida, and S.
aromaticum, which are considered bacteriostatic against S.
mutans. Among the selected EO chosen to be fractionated,
only that obtained from B. dracunculifolia was bacteriostatic.
Most fractions from selected EO were bactericidal, except for
Ag4, Cs1, Ls2, and Bd2, considered bacteriostatic against S.
mutans (Table 2). Based on yield and antimicrobial activity,
Ag4, Bd2, Cs4, and Ls3 fractions were selected for further
evaluations.
3.3. Selected Active Fractions Activity against Smutans Biofilm.
Figure 1 shows the development of S. mutans biofilm
inhibiton after treatment with selected active fractions. Their
growth was measured by optic density at 575 nm. The result
showed that the selected active fractions tested at diﬀerent
concentrations were significantly diﬀerent (P < 0.05) from
the vehicle. Moreover, Cs4 and Bd2 fractions presented a
better performance since they inhibited more than 90% of
biofilm formation at lower concentrations (31.2 µg/mL).
3.4. pH-Drop Assay. The influence of selected active frac-
tions from EO on glycolytic pH-drop of S. mutans biofilm
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Figure 1: Influence of selected active fractions Ag4, Bd2, Cs4, and
Ls3 from selected essential oils at diﬀerent concentrations against
Streptococcus mutans biofilm formation. All fractions tested were
significantly diﬀerent from the vehicle at all concentrations tested.
Kruskal-Wallis test (P < 0.05).
formation in the presence of excess glucose was not signif-
icant (P > 0.05) for all fractions tested (Ag4, Bd2, Cs4, and
Ls3).
3.5. Chemical Characterization of Fractions Constituents. The
chemical composition of the selected EO and the selected
active fractions is shown in Table 3.
The analyses of EO and fractions indicated the presence
of volatile compounds, mainly mono- and sesquiterpenes.
We identified 28 compounds in the EO of A. gratissima,
representing 92.73% of the EO, 25 compounds in the
EO of B. dracunculifolia, representing 93.45% of the EO,
15 compounds in the EO of C. sativum, representing
91.93% of the EO, and four compounds in the EO of L.
sidoides, representing 100% of the EO. We also identified
19 compounds in fraction Ag4, representing 94.6% of the
fraction, 10 compounds in fraction Bd2, representing 83.06%
of the fraction, nine compounds in fraction Cs4, representing
89.71% of the fraction, and five compounds in fraction Ls3,
representing 99.7% of the fraction.
The major compounds identified in each selected EO
were: trans- and cis-pinocamphone, beta-pinene, and guaiol
in A. gratissima; trans-nerolidol and spathulenol in B.
dracunculifolia; 2-decen-1-ol and 1-decanol in C. sativum;
and thymol in L. sidoides. The major compounds identified
in each selected fractions were trans- and cis-pinocamphone
and guaiol in Ag3; trans-nerolidol, spathulenol, and ethyl
ester benzenepropanoic in Bd2; 2-decen-1-ol and 1-decanol
in Cs4; thymol in Ls3.
3.6. Scanning Electron Microscopy (SEM). The eﬀect of
selected active fractions against S. mutans biofilm formation
was evaluated by SEM. Figure 2 shows a reduction in
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Table 2: Selected EO and their fractions with yield results, MIC and MBC values, and MBC :MIC ratio.
Essential oil Fraction
Identification
MIC
(µg/mL)
MBC
(µg/mL)
Identification Yield (%)
MIC
(µg/mL)
MBC
(µg/mL)
MBC :MIC
ratio1
Aloysia
gratissima (Ag)
125–250 250–500
Ag1 28.9 250–500 500–1000 2 : 1
Ag2 17.9 250–500 500–1000 2 : 1
Ag3 20.1 62.5–125 500–1000 8 : 1
Ag42 14.4 31.2–62.5 62.5–125 2 : 1
Baccharis
dracunculifolia
(Bd)
62.5–125 250–500
Bd1 30.5 250–500 500–1000 2 : 1
Bd2 22.1 15.6–31.2 125–250 8 : 1
Coriandrum
sativum (Cs)
31.2–62.5 62.5–125
Cs1 6.6 125–250 500–1000 4 : 1
Cs2 4.9 125–250 250–500 2 : 1
Cs3 12.7 15.6–31.2 31.2–62.5 2 : 1
Cs4 30.9 15.6–31.2 31.2–62.5 1 : 1
Lippia sidoides
(Ls)
62.5–125 125–250
Ls1 13.6 250–500 500–1000 2 : 1
Ls2 33.3 62.5–125 250–500 4 : 1
Ls3 26 62.5–125 125–250 2 : 1
Ls4 6.1 62.5–125 125–250 2 : 1
Ls5 1.7 62.5–125 125–250 2 : 1
1
The fractions from selected EO were considered bactericidal when the MBC :MIC ratio was between 1 : 1 to 2 : 1, and bacteriostatic if this ratio was higher
than 2 : 1. 2The fractions in bold font were selected as active fractions and evaluated against S. mutans biofilm and for their antiproliferative action. The
subscript numbers of the fractions represent the numbers of parts obtained using the dry column fractionation.
biofilm formation. Biofilms were first developed as described
previously (Section 2.7.1), were treated with vehicle, or
had their active fractions selected at concentrations able
to inhibit more than 90% of S. mutans biofilm formation
(Ag4 at 62.5 µg/mL, Bd2 and Cs4 at 31.2 µg/mL, and Ls3 at
125 µg/mL).
3.7. Antiproliferative Assay. Most EOs and their selected
active fractions did not present activity against the human
normal cell line evaluated in this study or presented high
concentrations to totally inhibit its growth. TGI values are
shown in Table 4.
Among the EO evaluated, B. dracunculifolia and C.
sativum were the most active inhibitors of human tumor
cell lines growth, presenting selectivity for U251 (TGI =
38.2 µg/mL and TGI = 8.3 µg/mL, resp.) and OVCAR-3 (TGI
< 0.25 µg/mL for both). On the other hand, A. gratissima
and L. sidoides displayed the lowest activity, both presenting
selectivity for OVCAR-3 (TGI < 0.25 µg/mL for both) and
L. sidoides for PC-3 (TGI = 26.7 µg/mL). The reference
compound, doxorubicin, presented antiproliferative activity
against all cell lines, except for kidney (Table 4).
Table 4 also shows the activity of selected active frac-
tions. Ag4 and Ls3 fractions presented better results than
A. gratissima and L. sidoides EO, respectively, since these
fractions were not active against human normal cell lines
(TGI > 250 µg/mL) and showed lower TGI values, being
selective for 786-0 (TGI = 5.9 µg/mL and TGI = 26.7 µg/mL,
resp.). Cs4 fraction had better results than C. sativum EO
only against NCI-ADR/RES (TGI = 13.1 µg/mL and TGI
= 90 µg/mL, resp.). Bd2 displayed a better performance
than B. dracunculifolia EO against NCI-ADR/RES (TGI =
10.5 µg/mL and TGI = 59.2 µg/mL, resp.), 786-0 (TGI =
47.1 µg/mL and TGI = 49.5 µg/mL, resp.), and NCI-H460
(TGI = 76.8 µg/mL and TGI = 87.6 µg/mL, resp.).
4. Discussion
The activity of natural products, especially EO, against
microorganisms has been recently confirmed by several
studies focusing on antimicrobial activity of EO against
planktonic cells. However, bacteria growing in biofilms
exhibit a specific phenotype and are often, but not always,
more resistant to antimicrobial agents than their planktonic
counterparts [10, 11]. Thus, it is important to search
for natural products that have antibiofilm properties and
antimicrobial activity against oral pathogens [28].
This study aimed to evaluate the activity of EO and
their fractions against planktonic cells of S. mutans, and the
active fractions were evaluated against biofilm formed by S.
mutans. Also, EO and their active fractions were chemically
characterized and their activity against human normal and
tumor cell lines proliferation were determined.
The antimicrobial assay revealed low MIC values for
almost all 20 EOs and 15 fractions from the selected
EO tested. EO and the selected active fractions presented
strong activity against S. mutans, since natural products are
considered strong inhibitors of microbial activity, when MIC
values are lower than 500 µg/mL [29].
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Table 3: Major compounds of the selected active fractions from essential oils with their retention time (Rt), retention index (RI), and relative
percentage.
Rt (min) RI Compound Relative percentage1
Ag EO Ag4 Bd EO Bd2 Cs EO Cs4 Ls EO Ls3
4.02 899 Cyclohexanone — — — — — — 6.5 —
4.22 850 3-hexen-1-ol — — — 0.8 3.6 5.1 — —
5.87 977 Beta-pinene 12.0 — — — — — — —
7.2 1024 p-cymene — — — — — 17.3 —
13.08 1140 Trans-pinocarveol — 4.9 — — — — — —
14.09 1165 Trans-pinocamphone 16.0 36.7 — — — — — —
14.61 1177 Cis-pinocamphone 6.0 17.0 — — — — —
16.7 1274 2-decen-1-ol <E> — — — — 23.6 26.9 — —
16.86 1277 1-decanol — — — — 33.9 35.4 — —
17.76 1299
Trans-pinocarvyl
acetate
8.2 — — — — — — —
19.74 1300 Thymol — — — — — 65.8 97.8
19.95 1303 Carvacrol — — — — — — — 0.6
21.84 1349
Ethyl ester
benzenepropanoic
— — — 11.7 — — — —
22.57 1416 Trans-caryophyllene 7.2 — 10.7 — — — 10.5 —
24.86 1473 2-dodecen-1-ol — — — — 13.1 14.5 — —
25.04 14.78 Germacrene D — — 4.9 — — — — —
25.66 1493 Bicyclogermacrene 4.2 — 6.8 — — — — —
27.97 1553 M2 = 204 6.4 — — — — — —
30.59 1566 Trans-nerolidol — — 31.7 52.2 — — — —
31.05 1578 Spathulenol — — 13.6 11.5 — — — —
31.23 1582 Caryophyllene oxide 6.4 7.0 — 6.3 — — — 0.7
31.9 1600 Guaiol 8.5 12.7 — — — — — —
33.44 1641 Epi alpha cadinol — — — 3.1 — — — —
32.47 1674 2-tetradecen-1-ol <E> — — — — 5.5 5.2 — —
34.40 1668 Bulnesol — 3.5 — — — — — —
1
The selected active fractions Ag4, Bd2, Cs4, and Ls3 had their actions against S. mutans biofilm and their antiproliferative activity evaluated. Ag EO, Bd EO, Cs
EO, and Ls EO correspond to the following essential oils: Aloysia gratissima, Baccharis dracunculifolia, Coriandrum sativum, and Lippia sidoides, respectively.
Only the compounds with relative percentage above 3% are listed. 2M: molecular weight of a nonidentified compound.
These results demonstrate that the EO studied and
especially those selected (A. gratissima, B. dracunculifolia, C.
sativum, and L. sidoides) have potential for bioprospection of
new active biomolecules. The fractionation process adopted
showed good results, since the fractions obtained were more
active than the original EO (Table 2). This bioguided study
is a model for bioprospecting new drugs [30], and it can
be considered successful since we found active fractions
presenting higher activity than their respective EO.
Most EO and fractions studied showed MBC :MIC ratio
that enables them to be classified as bactericidal compounds.
This could be explained by their hydrophobicity, an impor-
tant characteristic that exists in EO and their fractions [31]
and may allow them to partition the lipids of the bacterial
cell membrane, turning them more permeable and leading
to leakage of ions and other cell constituents [32, 33]. On
the other hand, B. dracunculifolia EO and its selected active
fraction (Bd2) present compounds that could be capable
of infiltrating the cell and interact with cellular metabolic
mechanisms [34], demonstrating their bacteriostatic eﬀect.
Nevertheless, despite presenting bactericidal or bacteriostatic
eﬀect, the selected EO proved to be active against both
S. mutans planktonic cells and biofilm, demonstrating the
eﬀectiveness of the substances present in these EO, since it
is diﬃcult to disrupt S. mutans biofilm [35].
The selected active fractions were also tested against S.
mutans biofilm, and they were able to disrupt its formation at
all tested concentrations. This disruption was observed using
SEM, which showed the change the selected active fractions
caused in the structure of S. mutans biofilm.
At the concentrations tested, it was possible to observe
huge failures in S. mutans biofilm surface treated with
the active fractions when compared with the treatment
with the vehicle, which presented a more homogeneous
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Figure 2: Scanning electron microscopy of Streptococcus mutans biofilms treated with the selected active fractions from selected essential
oils and the vehicle. Images a, b, c, and d show the reduction of biofilm formation after treatment with Ag4, Bd2, Cs4, and Ls3 fractions,
respectively, compared with the treatment with the vehicle (image (e)) (magnification of 7000x).
Table 4: Total growth inhibition (TGI) of selected essential oils and their selected active fractions tested against normal human cell and
tumor cell lines.
Cell line TGI (µg/mL)1
Ag EO Ag4 Bd EO Bd2 Cs EO Cs4 Ls EO Ls3 Dox
Glioma (U251) >250 55.6 38.2 51.4 8.3 61.5 >250 94.9 0.92
Breast (MCF-7) >250 45.2 46.0 67.7 13.6 111.6 >250 56.6 3.3
Ovarian (NCI-
ADR/RES)
>250 50.6 59.2 10.5 90.0 13.1 >250 112.3 1.6
Kidney (786-0) >250 5.9 49.5 47.1 29.8 72.1 >250 26.7 >250
Lung
(NCI-H460)
>250 42.7 87.6 76.8 105.0 110.3 >250 79.8 4.9
Prostate (PC-3) 99.9 >250 >250 >250 118.1 141.9 26.7 >250 11.7
Ovarian
(OVCAR-3)
<0.25 47.6 <0.25 58.0 <0.25 73.7 <0.25 60.4 7.6
Keratinocytes
(HaCaT)
>250 >250 92.3 95.7 129.4 145.6 >250 >250 2.3
1
Data result from three replicates per treatment in two independent tests at 25◦C for 48 hours. Ag EO, Bd EO, Cs EO, and Ls EO correspond to the following
essential oils: Aloysia gratissima, Baccharis dracunculifolia, Coriandrum sativum, and Lippia sidoides, respectively. Ag4, Bd2, Cs4, and Ls3 are the selected active
fractions evaluated. Dox: doxorubicin (positive control).
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biofilm surface. These changes were also observed in another
study that tested the action of C. sativum and its bioactive
fraction against Candida albicans [11]. Moreover, the simple
conformational change in biofilm, caused by the action of the
selected active fractions, could make it more susceptible and
less virulent [4].
However, when the selected active fractions were tested
in order to evaluate their ability to reduce S. mutans acid
production, no significant results were observed (P > 0.05).
Therefore, the selected active fractions could not act on this
important virulence factor of S. mutans, diﬀerent from the
findings of another work with B. dracunculifolia extracts,
which showed significant reduction in production of acid
by this microorganism [36]. The diﬀerence between B.
dracunculifolia EO and the active extracts from this plant
may be attributed to the extraction method, which results in
diﬀerent compound mixtures with diﬀerent mechanisms of
action [37].
It is known that EOs are composed of numerous diﬀerent
chemical compounds, and their antimicrobial activity might
be attributed to several diﬀerent mechanisms, which could
explain the variations in their mode of action [38].
The present data suggest the occurrence of a separation
during the fractionation process of the selected EO in such
a way that the selected active fractions presented higher
amounts of bioactive compounds than their respective
EO. The main biologically active compounds found in
the selected active fractions were thymol, carvacrol, 2-
decen-1-ol, trans-nerolidol, spathulenol, ethyl ester benzene-
propanoic, trans-pinocamphone, cis-pinocamphone, and
guaiol. These compounds have been extensively described in
the literature for their eﬀect on microorganisms [39, 40].
Both forms of trans- and cis-pinocamphone are major
constituents of Ag4 fraction and were also found in Hyssopus
oﬃcinalis L. EO [41]. These compounds are responsible for
the antibacterial, antifungal, and antioxidant activities of H.
oﬃcinalis EO, demonstrating that they pass through the cell
wall and the plasma membrane, disrupting their structure
[41]. The bactericidal activity of Ag4 fraction observed in the
present study may be a consequence of this mode of action.
Trans-nerolidol and spathulenol, two compounds
present in Bd2 fraction, have been considered active against
unknown Gram-positive and Gram-negative bacteria [13].
Although spathulenol shows activity against S. mutans, its
mechanism of action still remains unknown [13].
Other studies showed that certain alcohols, such as 2-
decen-1-ol, have higher antimicrobial activity than aldehydes
against Candida ssp. [11, 16]. These alcohols were found in
Cs4 fraction and may be responsible for the action against
S. mutans biofilm. Furthermore, considering the mode of
action of C. sativum EO, it seems to result in bacterial cell
permeabilization, leading to the impairment of other cell
functions, such as membrane potential, respiratory activity,
or eﬄux pump activity [42].
Thymol is an optic isomer of carvacrol, and both
substances seem to make bacterial membrane more perme-
able [43]. In our study, both were found in Ls3 fraction as its
major components. Previous studies have shown that these
compounds present antimicrobial activity against fungi and
bacteria [44], including species of the genus Streptococcus
[12].
After determining the antimicrobial activity of a natural
product, it is important to verify if it also exhibits antipro-
liferative activity, mainly after its fractionation, a procedure
that may concentrate toxic compounds in the fractions that
present biological activity.
Based on TGI values, the selected EO and selected active
fractions could be classified as inactive (TGI > 50 µg/mL),
weakly active (15 µg/mL < TGI < 50 µg/mL), moderately
active (6.25 µg/mL < TGI < 15 µg/mL), and strongly active
(TGI < 6.25 µg/mL) [45]. The absence of activity was clearly
observed in this study since all selected EO and selected active
fractions were inactive against the human normal cell line
tested.
All EOs tested were selective against the ovarian tumor
cell line, showing potent activity. Ag4 showed potent activity
against the kidney tumor cell line, and Bd2 and Cs4 fractions
showed only moderate activity against the ovarian tumor cell
line. These results show the specificity of these EO and their
fractions against some tumor cell lines, an important and
desired characteristic for potential new chemotherapic drugs
[15].
It is known that EO compounds, such as monoterpenes,
have shown eﬀects on mevalonate metabolism, linked to the
maintenance of cell membrane, which could contribute to
terpene tumor suppressive action [46]. Thereby, the presence
of monoterpenes in the selected active fractions of our
studymay explain their antiproliferative actions against some
tumor cell lines [47]; however, more studies are required to
find the compounds of EO responsible for their anticancer
activity, since little is known about essential oils and their
antiproliferative activity.
5. Conclusion
The results of the present study indicate that all EO and
fractions tested showed good antimicrobial activity, but only
those showing activity at low concentrations were taken
into consideration and fractionated for bioprospection of
new agents against S. mutans. Among these fractions, the
selected active fractions were able to disrupt S. mutans
biofilm formation, did not inhibit normal cell line growth,
and weremore specific against human tumor cell lines. These
features enable them to be tested in further studies and help
the discovery of new bioactive molecules.
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